Leukemia & Lymphoma最新文献_第9页

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-19 DOI: 10.1080/10428194.2025.2466101

Christine Gruessner, Adrian Wiestner, Clare Sun

{"title":"Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.","authors":"Christine Gruessner, Adrian Wiestner, Clare Sun","doi":"10.1080/10428194.2025.2466101","DOIUrl":"https://doi.org/10.1080/10428194.2025.2466101","url":null,"abstract":"Bruton tyrosine kinase (BTK), an essential component of the B-cell receptor (BCR) signaling pathway, is a validated target in chronic lymphocytic leukemia. Ibrutinib, acalabrutinib, and zanubrutinib are covalent BTK inhibitors (cBTKi) that bind to residue C481, leading to sustained target inhibition. A significant proportion of patients develop resistance to continuous cBTKi therapy, predominantly via mutations in BTK and its immediate downstream effector, PLCG2. The noncovalent BTKi pirtobrutinib does not require binding to C481 and can restore BTK inhibition after progression on a cBTKi. However, non-C481 BTK mutations conferring resistance to pirtobrutinib have been identified. Furthermore, the scaffolding function of BTK, activation of bypass signaling pathways, and the tumor microenvironment may contribute to BTKi resistance. Targeting BTK for degradation is an emerging strategy that appears effective against multiple BTK mutations, and inhibitors of downstream BCR signaling proteins are under development. This review addresses BTKi resistance mechanisms and therapeutic approaches after cBTKi failure.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-18 DOI: 10.1080/10428194.2025.2452341

Anna Shestakova, Nahideh Haghighi, Ying Zhang, Jana Tarabay, Mark G Evans, Anton Burtsev, Jefferson Y Chan, Ashley Gamayo, Xiaohui Zhao, Susan O'Brien, Fabiola Quintero-Rivera, Sherif A Rezk

引用次数: 0

High burden and poor outcomes of myelodysplastic neoplasms (MDS) in the real-world: a 10-year audit of three Australian hospitals.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-18 DOI: 10.1080/10428194.2025.2467783

Zoe Loh, Michael Ashby, Marzia Rahman, Evangeline Y Wong, Doen Ming Ong, Susan Morgan, Chong Chyn Chua

引用次数: 0

CALR-mutated myeloproliferative neoplasms.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-17 DOI: 10.1080/10428194.2025.2465551

Valentina Bellani, Barbara Mora, Alessandra Iurlo, Francesco Passamonti

引用次数: 0

(CAR-)T cell dynamics following chimeric antigen receptor T cells for large B cell lymphoma: a translational tale.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-13 DOI: 10.1080/10428194.2025.2456096

M Gambella, S Carlomagno, A M Raiola, S Sivori, E Angelucci

{"title":"(CAR-)T cell dynamics following chimeric antigen receptor T cells for large B cell lymphoma: a translational tale.","authors":"M Gambella, S Carlomagno, A M Raiola, S Sivori, E Angelucci","doi":"10.1080/10428194.2025.2456096","DOIUrl":"https://doi.org/10.1080/10428194.2025.2456096","url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough in the treatment of B-cell malignancies. CAR-T cells infusion generally follows a chemotherapy regimen whose lymphodepleting properties create a favorable environment for the expansion of engineered T cells. While this process appears straightforward, emerging evidence reveals that complex mechanisms, collectively representing immune dynamics following CAR-T cell infusion, influence CAR-T cells behavior. In advance of infusion, a final-product enriched with less stressed CAR-T cells can improve their expansion and persistence, providing a biological rationale for early apheresis and administration. Following infusion, the emergence of dysfunctional CAR-T subpopulations, like regulatory or NK-like CAR-T cells, can impair efficacy. The recovery of non-CAR transduced T cells adds further complexity, as these cells could either impact outcomes or exacerbate complications, such as infections or prolonged cytopenia. In this review, we summarize the latest advances in understanding the immune dynamics following CAR-T cell infusion for large B-cell lymphomas, with a focus on both CAR-engineered and native T cell populations, and their impact on treatment efficacy and patient outcomes.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-12 DOI: 10.1080/10428194.2025.2461663

Connor Frey, Mahyar Etminan

引用次数: 0

Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-10 DOI: 10.1080/10428194.2025.2460046

Yao Sun, Na Liu, Yingjie Liu, Jing Deng, Jiang Du, Liangding Hu

引用次数: 0

A pilot study of lower doses of ibrutinib: patient body weight does not correlate with plasma ibrutinib levels during therapy.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-08 DOI: 10.1080/10428194.2025.2461672

Lisa S Chen, Prithviraj Bose, Wei Qiao, Yongying Jiang, Qi Wu, Nichole D Cruz, Michael J Keating, Varsha Gandhi

引用次数: 0

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-08 DOI: 10.1080/10428194.2025.2455489

Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye, Michael S Khodadoust, Javier Munoz, Paul A Hamlin, Youn H Kim, Ryan A Wilcox, Manish R Patel, Greg Coffey, Alison Innes, Andreas Betz, Jaymes Holland, Cristina B Guzman, Sonali M Smith

{"title":"Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.","authors":"Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye, Michael S Khodadoust, Javier Munoz, Paul A Hamlin, Youn H Kim, Ryan A Wilcox, Manish R Patel, Greg Coffey, Alison Innes, Andreas Betz, Jaymes Holland, Cristina B Guzman, Sonali M Smith","doi":"10.1080/10428194.2025.2455489","DOIUrl":"https://doi.org/10.1080/10428194.2025.2455489","url":null,"abstract":"In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH], n = 29); PTCL-not otherwise specified [NOS], n = 11; and Other, n = 25) received 30 mg oral cerdulatinib, a reversible dual inhibitor of spleen tyrosine kinase and Janus kinase, twice daily in 28-day cycles until disease progression or unacceptable toxicity. Overall response rate (ORR) was 36.2% (12 complete responses [CR],9 partial responses [PR], and 14 stable disease); median time to response was 1.9 months. ORR was 51.9% for AITL/TFH (10 CR, 4 PR) and 31.8% for Other (2 CR, 5 PR); median duration of response was 12.9 and 5.3 months, respectively. The most common grade ≥3 treatment-emergent adverse events were asymptomatic amylase elevation (23.1%), anemia (20.0%), and asymptomatic lipase elevation (18.5%). These data suggest clinical activity and acceptable tolerability for cerdulatinib in patients with relapsed/refractory PTCL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-08 DOI: 10.1080/10428194.2025.2460737

Fabian Lang, Andreas Voss, Guido Kobbe, Christian Junghanss, Joachim Beck, Andreas Viardot, Knut Wendelin, Jens Panse, Lisa Heberling, Vladan Vucinic, Boris Böll, Max Topp, Dieter Hoelzer, Hubert Serve, Nicola Goekbuget, Oliver G Ottmann, Heike Pfeifer

{"title":"Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.","authors":"Fabian Lang, Andreas Voss, Guido Kobbe, Christian Junghanss, Joachim Beck, Andreas Viardot, Knut Wendelin, Jens Panse, Lisa Heberling, Vladan Vucinic, Boris Böll, Max Topp, Dieter Hoelzer, Hubert Serve, Nicola Goekbuget, Oliver G Ottmann, Heike Pfeifer","doi":"10.1080/10428194.2025.2460737","DOIUrl":"https://doi.org/10.1080/10428194.2025.2460737","url":null,"abstract":"Imatinib (IMA) plus chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) is established treatment for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). We investigated the use of dasatinib (DASA) combined with intensive chemotherapy in ALL (18-55 years) first-line in a prospective, multicenter phase II trial by the GMALL study group. 140 mg DASA QD was used with a pediatric-based induction and consolidation chemotherapy according to GMALL 07/2003 protocol with recommended consecutive HCT. Nineteen of 20 planned patients were enrolled in 12 centers. The hematologic CR rate after induction was 79% with an overall MRD negativity rate of 62.5%. Six patients died during induction and two discontinued therapy. This regimen achieved deep molecular responses but was associated with a higher than expected early mortality (21%) and was stopped prematurely due to toxicities. The GMALL therefore adopted a combination of low intensity chemotherapy plus IMA as its current induction regimen.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0